HER-2 expression

P1, N=108, Recruiting, Daiichi Sankyo | Active, not recruiting --> Recruiting

P2, N=50, Not yet recruiting, George Washington University | Initiation date: May 2026 --> Sep 2026

HER2-low GC helps refine GC classification and is associated with higher PD-L1 expression, supporting immunotherapy strategies. Further research is needed to explore its clinical and therapeutic value in personalized precision treatment.

P1, N=16, Recruiting, Memorial Sloan Kettering Cancer Center

Awareness of definitional sensitivity at receptor cut-off margins is essential for accurate reporting, avoidance of misclassification and informed multidisciplinary decision-making. Recognition of TNBC as a biologically heterogeneous spectrum has implications for therapeutic selection, trial eligibility and future refinement of classification systems.

Our findings revealed that statin use significantly enhanced the efficacy of T-DXd in both a preclinical HER2-negative rat model and patients with HER2-positive mBC. Prospective clinical trials are warranted to validate these observations.

These findings support the existence of greater variability in surrogate and intrinsic molecular subtypes within secretory carcinomas, providing potential personalized therapeutic strategies for the treatment of these patients.

P1/2, N=178, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

Therefore, these findings suggest that the remarkable response of HER2-positive DCIS in this case may be attributable to the HER2-inhibitory effect of osimertinib. Further research is warranted to determine whether osimertinib could serve as a potential treatment option for HER2-positive breast cancer, including DCIS.

In the real-world setting, RC48 shows some clinical efficacy and a manageable safety profile in patients with HER2-expressing advanced gastric cancer. These findings provide useful information for clinical practice.

Multi-platform and multi-omics profiling in this large unique cohort of longitudinal TNBC samples revealed distinct patterns of expression and dynamic changes of key biomarkers of interest for targeted therapies. Given variability with manual IHC scoring, improved methods for quantification of expression may help optimize treatment selection in an individualized manner.

HER2-low early breast cancer shows lower pCR after neoadjuvant therapy but better long-term survival. These findings support the clinical relevance of HER2-low as a biologically meaningful subgroup within HER2-negative disease, while its status as a stable and independent subtype still requires further validation through prospective studies, standardized testing, and multi-omics investigation.